-
Mashup Score: 0FDA Approval of Calquence Combo Brings Optimism in MCL - 6 day(s) ago
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0
The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Phase 2 Trial of Firi-Cel CAR T-Cell Therapy Discontinued in Lymphoma #Oncology #lymsm https://t.co/AYz8ZzPK1Q
-
-
Mashup Score: 0FDA Approval of Calquence Combo Brings Optimism in MCL - 12 day(s) ago
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
FDA Approval of Calquence Combo Brings Optimism in MCL @US_FDA @LymphClinician @cityofhope #Oncology #lymsm https://t.co/nZHL3TTLd5
-
-
Mashup Score: 2Liso-Cel Earns CHMP Recommendation for R/R Follicular Lymphoma - 23 day(s) ago
The EMA’s CHMP has recommended the approval of liso-cel for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Liso-Cel Earns CHMP Recommendation for R/R Follicular Lymphoma #oncology #lymsm https://t.co/XZWdAYyhZa
-
-
Mashup Score: 6huCART19-IL18 Is Tolerable, Induces Responses in CAR T-Cell–Pretreated R/R Lymphoma - 7 month(s) ago
Armored huCART19-IL18 treatment was tolerable in patients with relapsed/refractory lymphomas who progressed after CD19-directed CAR T-cell therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Armored huCART19-IL18 was feasible, well tolerated, and elicited durable responses in relapsed/refractory lymphomas. #oncology #lymsm https://t.co/ifc6vXOekv
-
-
Mashup Score: 6huCART19-IL18 Is Tolerable, Induces Responses in CAR T-Cell–Pretreated R/R Lymphoma - 7 month(s) ago
Armored huCART19-IL18 treatment was tolerable in patients with relapsed/refractory lymphomas who progressed after CD19-directed CAR T-cell therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Armored huCART19-IL18 was feasible, well tolerated, and elicited durable responses in relapsed/refractory lymphomas. #oncology #lymsm https://t.co/ifc6vXOekv
-
-
Mashup Score: 6huCART19-IL18 Is Tolerable, Induces Responses in CAR T-Cell–Pretreated R/R Lymphoma - 7 month(s) ago
Armored huCART19-IL18 treatment was tolerable in patients with relapsed/refractory lymphomas who progressed after CD19-directed CAR T-cell therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Armored huCART19-IL18 was feasible, well tolerated, and elicited durable responses in relapsed/refractory lymphomas. #oncology #lymsm https://t.co/ifc6vXOekv
-
-
Mashup Score: 6huCART19-IL18 Is Tolerable, Induces Responses in CAR T-Cell–Pretreated R/R Lymphoma - 8 month(s) ago
Armored huCART19-IL18 treatment was tolerable in patients with relapsed/refractory lymphomas who progressed after CD19-directed CAR T-cell therapy.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Armored huCART19-IL18 was feasible, well tolerated, and elicited durable responses in relapsed/refractory lymphomas. #oncology #lymsm https://t.co/ifc6vXOekv
-
-
Mashup Score: 1Current Treatment Options in Third-line MCL - 10 month(s) ago
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Want to learn more from the experts themselves? Listen here as medical oncologists from insitutions across the US gather to discuss third-line treatment options available for patients w/ MCL. @GregNowakowski @JenCrombieMD @lymphomaphilia #oncology #lymsm https://t.co/rgP5XbvPhE
-
-
Mashup Score: 4Brentuximab Vedotin Plus Lenalidomide and Rituximab Generates OS Benefit in Previously Treated DLBCL - 11 month(s) ago
Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Brentuximab Vedotin Plus Lenalidomide and Rituximab Generates OS Benefit in Previously Treated DLBCL #oncology #lymsm https://t.co/jyHIYaDFty
-
FDA Approval of Calquence Combo Brings Optimism in MCL @US_FDA @LymphClinician @cityofhope #Oncology #lymsm https://t.co/nZHL3TTLd5